Q4 2024 Vimta Labs Ltd Earnings Call Transcript
Key Points
- Vimta Labs Ltd (BOM:524394) reported a strong EBITDA margin improvement, reaching 31.1% in Q4 FY24, up by 353 basis points sequentially.
- The company maintained a net debt-free balance sheet with cash and cash equivalents of INR258 million.
- Vimta Labs Ltd (BOM:524394) is nearing the completion of its new life sciences expansion project at Genome Valley, which is expected to contribute significantly to future growth.
- The company has initiated long-term partnerships with leading global pharmaceutical and animal health companies, which are expected to drive future growth.
- The food testing segment showed a decent rebound in the second half of FY24 due to improved supply chain and increased focus on food safety by the Indian government.
- Revenues from operations for FY24 remained flat at INR3,183 million compared to FY23.
- Profit after tax in FY24 decreased to INR410 million from INR482 million in FY23, reflecting a decline in PAT margin to 12.7%.
- The start of the new pharma facility was delayed by a couple of months, pushing the expected commercial operations to Q2 FY25.
- The company faced challenges in the clinical research segment due to geopolitical issues and economic slowdowns, impacting pharmaceutical testing.
- Vimta Labs Ltd (BOM:524394) had to retrench some of its diagnostic expansion, reducing the number of labs from 19 to 17, indicating challenges in scaling this segment.
Ladies and gentlemen, good day, and welcome to Vimta Labs Limited quarter four investor conference call hosted by Systematix Institutional Equities. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Vishal Manchanda from Systematix Institutional Equities. Thank you, and over to you, sir.
Thank you, Sagar. Good afternoon, everyone. On behalf of Systematix Institutional Equities, I welcome you to the Q4 and full year FY24 earnings call of Vimta Labs. We thank the Vimta Labs management for giving us an opportunity to host the call.
Today, we have with us the senior management of Vimta represented by Ms. Harita Vasireddi, Managing Director; Mr. Satya Sreenivas Neerukonda, Executive Director; Mr. Narahai Naidu, Chief Financial Officer; and Ms. Sujani Vasireddi, Company Secretary.
I'll now hand over the call to the company management for opening remarks. Over to you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
